Tyler Curiel holds an MD from Duke and a master's in public health from Harvard. His postgraduate medical education combined internal medicine, infectious diseases and medical oncology. His laboratory has made seminal contributions to tumor immunology and immunotherapy that are helping shape the current resurgence of cancer immunotherapy, performing pivotal clinical human trials of to establish new concepts in cancer immunotherapy. His group also studies cancer prevention and age effects on cancer immunity and immunotherapy, and studies the basis for autoimmunity.